Phoenix Artificial Kidney Center (FMC) is a medicare approved dialysis facility center in Peoria, Arizona and it has 21 dialysis stations. It is located in Maricopa county at 13090 N 94th Dr Ste 100, Peoria, AZ, 85381. You can reach out to the office of Phoenix Artificial Kidney Center (FMC) at (623) 974-5851. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Phoenix Artificial Kidney Center (FMC) has the following ownership type - Profit. It was first certified by medicare in March, 1979. The medicare id for this facility is 032503 and it accepts patients under medicare ESRD program.
Name | Phoenix Artificial Kidney Center (FMC) |
---|---|
Location | 13090 N 94th Dr Ste 100, Peoria, Arizona |
No. of Dialysis Stations | 21 |
Medicare ID | 032503 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
13090 N 94th Dr Ste 100, Peoria, Arizona, 85381 | |
(623) 974-5851 | |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
NPI Number | 1497867394 |
Organization Name | Phoenix Artificial Kidney Center |
Doing Business As | Bio-medical Applications Of Arizona, Llc |
Address | 13090 N 94th Dr Peoria, Arizona, 85381 |
Phone Number | (623) 972-8154 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
NPI Number | 1063477727 |
Organization Name | Four Corners Dialysis Center |
Doing Business As | Trc - Four Corners Dialysis Clinics Llc |
Address | 801 W Broadway Farmington, New Mexico, 87401 |
Phone Number | (505) 325-2827 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 78% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 10% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 63% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 16% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 89% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 11% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 78% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Dialysis patients with Hemoglobin data | 17 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 6 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 76 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 634 |
Percentage of adult patients getting regular hemodialysis at the center | 99 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Phoenix Artificial Kidney Center (FMC) with elevated calcium levels.
Patients with hypercalcemia | 85 |
Hypercalcemia patient months | 722 |
Patients with Serumphosphor | 90 |
Patients with Serumphosphor less than 3.5 mg/dL | 10 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 53 |
Patient months included in arterial venous fistula and catheter summaries | 248 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 76 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 4 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 66 |
Hospitalization Rate in facility | 362.3 (Worse than Expected) |
Hospitalization Rate: Upper Confidence Limit | 565.9 |
Hospitalization Rate: Lower Confidence Limit | 239.3 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Phoenix Artificial Kidney Center (FMC) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 35.3 (As Expected) |
Readmission Rate: Upper Confidence Limit | 49.1 |
Readmission Rate: Lower Confidence Limit | 22.9 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Phoenix Artificial Kidney Center (FMC) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .74 (As Expected) |
SIR: Upper Confidence Limit | 1.79 |
SIR: Lower Confidence Limit | .24 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Phoenix Artificial Kidney Center (FMC)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 51 |
Transfusion Rate in facility | 43.1 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 139.9 |
Transfusion Rate: Lower Confidence Limit | 15.3 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Phoenix Artificial Kidney Center (FMC) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 331 |
Mortality Rate in facility | 20.8 (As Expected) |
Mortality Rate: Upper Confidence Limit | 27.2 |
Mortality Rate: Lower Confidence Limit | 15.7 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago
Phoenix Artificial Kidney Center (FMC) Location: 13090 N 94th Dr Ste 100, Peoria, Arizona, 85381 Phone: (623) 974-5851 |
Sweetwater Ridge Dialysis (DVA) Location: 7362 W Thunderbird Rd Suite 104, Peoria, Arizona, 85381 Phone: (623) 486-0327 |
News Archive
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.
An international multidisciplinary consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient-reported outcome (PRO) data in cancer clinical trials.
› Verified 4 days ago